$ Value
$0
Shares
154,000
Price
$0
Filed
Feb 10
Insider
Name
Carter Todd Alfred
Title
Chief Scientific Officer
CIK
0001944011
Roles
Transaction Details
Transaction Date
2026-02-06
Code
A
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
154,000
Footnotes
Consists of shares of common stock issuable under an aggregate of 33,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. | This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.
Filing Info
Carter Todd Alfred's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-24 | VYGR | ▼ | $16K |
| 2026-02-18 | VYGR | ▼ | $11K |
| 2026-02-10 | VYGR | ▼ | $14K |
| 2026-02-06 | VYGR | A | $0 |
| 2026-02-06 | VYGR | A | $0 |
Other Insiders at VYGR (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Sandrock Alfred
President and CEO
|
— | $184K | 2026-04-02 |
|
Jorgensen Nathan D.
Chief Financial Officer
|
— | $18K | 2026-02-24 |
|
Swartz Robin
COO & CBO
|
— | $55K | 2026-02-24 |
|
Carter Todd Alfred
Chief Scientific Officer
|
— | $41K | 2026-02-24 |
|
Ferguson Toby
Chief Medical Officer
|
— | — | 2026-02-06 |
|
Shiferman Gregory L.
SVP and General Counsel
|
— | — | 2026-04-01 |